-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $109

Benzinga·08/13/2026 13:36:00
Listen to the news
Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $106 to $109.